Altering gene expression in modified T cells and uses thereof
The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
1. A CRISPR-modified T cell comprising:
(i) a CRISPR-mediated insertion or deletion in a TCR α chain (TRAC) gene locus causing downregulated gene expression of the endogenous TCR α chain gene, wherein at least one of the insertions or deletions are in the TRAC gene nucleotide sequence corresponding to SEQ ID NO: 1;
(ii) a CRISPR-mediated insertion or deletion in a TCR β chain (TRBC) gene locus causing downregulated gene expression of the endogenous TCR β chain gene; and
(iii) a nucleic acid encoding a modified T cell receptor (TCR) that is an 8F TCR comprising affinity for an NY-ESO-1 tumor associated antigen (TAA) on a target cell.
2. The CRISPR-modified T cell of claim 1 , wherein the modified TCR is selected from the group consisting of a high affinity TCR and a chimeric TCR.
3. The CRISPR-modified T cell of claim 1 , wherein the modified TCR comprises at least one disulfide bond.
4. The CRISPR-modified T cell of claim 1 , wherein the modified TCR comprises a TCR alpha chain and TCR beta chain.
5. The CRISPR-modified T cell of claim 1 , wherein the modified TCR comprises a co-stimulatory signaling domain at a C′ terminal of at least one of the chains.
6. The CRISPR-modified T cell of claim 5 , wherein the co-stimulatory signaling domain is a 4-1BB co-stimulatory signaling domain.
7. The CRISPR-modified T cell of claim 4 , wherein the TCR beta chain comprises at least one N-deglycosylation.
8. The CRISPR-modified T cell of claim 4 , wherein the TCR alpha chain comprises at least one N-deglycosylation.
9. The CRISPR-modified T cell of claim 1 , wherein the modified TCR comprises at least one murine constant region.
10. The CRISPR-modified T cell of claim 1 , wherein the modified TCR has higher affinity for the target TAA when compared with the affinity of a wildtype TCR for the target TAA.
11. A pharmaceutical composition comprising the CRISPR-modified T cell of claim 1 and a pharmaceutically acceptable carrier.
12. The CRISPR-modified T cell of claim 1 , further comprising a CRISPR-mediated insertion or deletion in a PD1 gene locus capable of downregulating gene expression of an endogenous PD1 gene.
13. A CRISPR-modified T cell comprising:
(i) a CRISPR-mediated insertion or deletion in a TCR α chain (TRAC) gene locus capable of downregulating gene expression of an endogenous TCR α chain gene, wherein at least one of the insertions or deletions are in the TRAC gene sequence corresponding to SEQ ID NO: 1;
(ii) a CRISPR-mediated insertion or deletion in a TCR β chain (TRBC) gene locus capable of downregulating gene expression of an endogenous TCR β chain gene; and
(iii) a nucleic acid encoding an 8F T cell receptor (TCR) comprising affinity for NY-ESO-1 on a target cell.
14. A CRISPR-modified T cell comprising:
(i) a CRISPR-mediated insertion or deletion in a TCR α chain (TRAC) gene locus capable of downregulating gene expression of an endogenous TCR α chain gene, wherein at least one of the insertions or deletions are in the TRAC gene sequence corresponding to SEQ ID NO: 1;
(ii) a CRISPR-mediated insertion or deletion in a TCR β chain (TRBC) gene locus capable of downregulating gene expression of an endogenous TCR β chain gene;
(iii) a CRISPR-mediated insertion or deletion in a PD1 gene locus capable of downregulating gene expression of an endogenous PD1 gene; and
(iv) a nucleic acid encoding an 8F T cell receptor (TCR) comprising affinity for NY-ESO-1 on a target cell.